27 results
8-K
EX-2.1
RVLPQ
RVL Pharmaceuticals plc
27 Nov 23
Bankruptcy or Receivership
4:06pm
, or in connection with the Plan and incident to the Chapter 11 Cases, including from the Professional Fee Escrow, has been approved by, or is subject to the approval
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation
8-K
EX-1.1
xxfrgnwarxr9js2kgko
12 Oct 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:46pm
8-K
EX-10.2
pxosubi9azb
6 Oct 21
Entry into a Material Definitive Agreement
4:22pm
8-K
EX-1.1
s7k6u tt1u
8 Sep 21
Other Events
7:10am
8-K
EX-2.1
w8mt8ejtcx9qu72k7fw
30 Jun 21
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
6:04am
8-K
EX-99.1
wn7tbwodajjx9h0
31 Jul 20
Is (I) Not Material and (Ii) Would Likely Cause Competitive Harm to the Company If
4:33pm
8-K
EX-1.1
v52n4l ee3595a
15 Jul 20
Other Events
4:52pm
10-K
EX-4.1
3ux468i 0u8i
28 Mar 19
Annual report
12:00am
S-1/A
EX-4.1
5b4zqh5mech0r87ck2jv
1 Oct 18
IPO registration (amended)
12:00am
DRS/A
EX-10.1
utda60
13 Jul 18
Draft registration statement (amended)
12:00am
DRS/A
EX-2.2
87t7 lruetbqtoow
13 Jul 18
Draft registration statement (amended)
12:00am